Back
Biological Modulation of Parp Inhibition in Triple Negative Breast Cancer, a Combinational Approach Implementing Multitargeted Epigenetic Therapy (Mtet) with Parp Inhibition, in Advanced Breast Cancer: A Case Study
M. Nezami, Steve Hager, Julie Taguchi
J. Cancer Ther. Vol.9 No.9, September 11, 2018  DOI: 10.4236/jct.2018.99060
       (PDF  2152K)     HTML      XML
N-Myc Inhibition: Advances in Neuroblastoma Treatment
Md Kamrul Hasan
CellBio Vol.6 No.3, September 30, 2017  DOI: 10.4236/cellbio.2017.63003
       (PDF  282K)     HTML      XML
The PARP-1 Inhibitor Olaparib Causes Retention of γ-H2AX Foci in BRCA1 Heterozygote Cells Following Exposure to Gamma Radiation
Emma C. Bourton, Piers N. Plowman, Amanda J. Harvey, Sheba Adam Zahir, Christopher N. Parris
J. Cancer Ther. Vol.4 No.11, December 17, 2013  DOI: 10.4236/jct.2013.411A006
       (PDF  449K)     HTML     
Impact of Olaparib for Maintenance Monotherapy on Survival in Breast and Ovarian Cancer: A Systematic Review and Pooled Analysis of Published Trials
Jun Dong, Tian Zhang, Bixiu Wen
Int. J. Med. Phys. Clin. Eng. Radiat. Oncol. Vol.4 No.4, November 11, 2015  DOI: 10.4236/ijmpcero.2015.44040
       (PDF  723K)     HTML      XML
CHK21100delC, I157T, IVS2 +IG > A, BRCA1 and BRCA2 Mutation Analysis in JF305: A Pancreatic Cancer Cell Line
Charles Ndawula Jr., Xueli Yang, Xiaohai Gong, Jian Jin
J. Biosci. Med. Vol.2 No.1, March 21, 2014  DOI: 10.4236/jbm.2014.21007
       (PDF  933K)     HTML     
 
 
Top